Stephanie Saundh

Stephanie Saundh


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2021 in Crystals
Verified
Journal Article
Open access
PDF file
NPNarsimha Pujari
Narsimha Pujari
SSStephanie Saundh
Stephanie Saundh
FBFrancis A. Biotech
Francis A. Biotech
Blaine MooersBlaine Mooers
Blaine Mooers
AFAdrian Ferré-D'Amaré
Adrian Ferré-D'Amaré
ALAdeline Leung
Adeline Leung
X-ray crystallography remains a powerful method to gain atomistic insights into the catalytic and regulatory functions of RNA molecules. However, the technique requires the preparation of diffraction-quality crystals. This is often a resource- and time-consuming venture because RNA crystallization is hindered by the conformational heterogeneity of RNA, as well as the limited opportunities for stereospecific intermolecular interactions between RNA molecules. The limited success at crystallization explains in part the smaller number of RNA-only structures in the Protein Data Bank. Several approaches have been developed to aid the formation of well-ordered RNA crystals. The majority of these are construct-engineering techniques that aim to introduce crystal contacts to favor the formation of well-diffracting crystals. A typical example is the insertion of tetraloop–tetraloop receptor pairs into non-essential RNA segments to promote intermolecular association. Other methods of promoting crystallization involve chaperones and crystallization-friendly molecules that increase RNA stability and improve crystal packing. In this review, we discuss the various techniques that have been successfully used to facilitate crystal packing of RNA molecules, recent advances in construct engineering, and directions for future research in this vital aspect of RNA crystallography.

30 November 2020 in ACS Chemical Neuroscience
Verified
Journal Article
Closed access
SSStephanie Saundh
Stephanie Saundh
DPDebasis Patnaik
Debasis Patnaik
SGSteve Gagné
Steve Gagné
JBJoshua A. Bishop
Joshua A. Bishop
SLSean Lipsit
Sean Lipsit
ALAdeline Leung
Adeline Leung

29 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
SYSatoko Yamaoka
Satoko Yamaoka
ZMZeineb M’hAmdi
Zeineb M’hAmdi
LWLin Wang
Lin Wang
VSVaille A. Swenson
Vaille A. Swenson
KMKristin L. McNally
Kristin L. McNally
HEHideki Ebihara
Hideki Ebihara
Uncontrolled systemic inflammatory responses are a critical pathological feature of fatal Ebola virus (EBOV) infection. While some inflammatory responses may originate from mononuclear phagocytes (MNPs), nonimmune cells vastly outnumber MNPs and may be an important source of inflammation. Here, we demonstrated that highly virulent EBOV induced a high and sustained pro-inflammatory response compared to less virulent ebolaviruses in non-MNPs through TLR4-independent NF-κB activation. We identified the EBOV matrix protein VP40 as a potent activator of NF-κB in non-MNPs, whose intrinsic inflammatory activation ability is higher than VP40 proteins from less virulent ebolaviruses. This suggests that VP40 is a virulence determinant inducing distinct degrees of pro-inflammatory responses among ebolaviruses. Mechanistically, VP40 activated the NF-κB signaling pathway, primarily via TNFR1 using a ligand-independent mechanism. These findings reveal mechanisms that may drive systemic inflammation and promote EBOV pathogenesis, suggesting potential therapeutic strategies to mitigate immune dysregulation in severe EBOV infections.

18 June 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
SSStephanie Saundh
Stephanie Saundh
DPDebasis Patnaik
Debasis Patnaik
SGSteve Gagné
Steve Gagné
JBJosh Bishop
Josh Bishop
SLSean Lipsit
Sean Lipsit
ALAdeline Leung
Adeline Leung
Glycogen Synthase Kinase 3-beta (GSK3β) is a critical regulator of several cellular pathways involved in neuroplasticity and is a potential target for neurotherapeutic development in the treatment of neuropsychiatric and neurodegenerative diseases. The majority of efforts to develop inhibitors of GSK3β have been focused on developing small molecule inhibitors that compete with ATP through direct interaction with the ATP binding site. This strategy has presented selectivity challenges due to the evolutionary conservation of this domain within the kinome. The Disrupted in Schizophrenia (DISC1) protein, has previously been shown to bind and inhibit GSK3β activity. Here, we report the characterization of a 44-mer peptide derived from human DISC1 (hDISCtide) that is sufficient to both bind and inhibit GSK3β in a non-competitive mode that is distinct from classical ATP competitive inhibitors. Based on multiple independent biochemical and biophysical assays, we propose that hDISCtide interacts at two distinct regions of GSK3β: an inhibitory region that partially overlaps with the binding site of FRATide, a well-known GSK3β binding peptide, and a specific binding region that is unique to hDISCtide. Taken together, our findings present a novel avenue for developing a peptide-based selective inhibitor of GSK3β.